At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 298 enrolled
Drug / intervention
PG324 Ophthalmic Solution 0.01% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Patients With Elevated Intraocular Pressure
In Brief
A Phase 2 clinical trial evaluating PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, and 2 other interventions for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 298 participants across 23 sites.
Detailed Summary
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedFeb 2014
Primary CompletionJun 2014
TodayJul 2026
First PostedFeb 7, 2014
Enrollment StartJan 1, 2014
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.4 years ago
Interventions
PG324 Ophthalmic Solution 0.01%drug
1 drop in the evening (PM), once daily (QD), both eyes (OU)
PG324 Ophthalmic Solution 0.02%drug
1 drop in the evening (PM), once daily (QD), both eyes (OU)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%drug
1 drop in the evening (PM), once daily (QD), both eyes (OU)
Latanoprost Ophthalmic Solution 0.005%drug
1 drop in the evening (PM), once daily (QD), both eyes (OU)